Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 4/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.56 |
| ▸ | CDC25A | P30304 | 2/20 | 0.55 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.55 |
| ▸ | POLA1 | P09884 | 1/20 | 0.55 |
| ▸ | ST6GAL1 | P15907 | 2/20 | 0.55 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.52 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | CASP7 | P55210 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24015370 | 0.89 | VDR (0.55) | VDRUSP2GPBAR1CDC25AABCC4 | |
| SCHEMBL10598505 | 0.88 | CDC25A (0.71) | VDRUSP2GPBAR1CDC25AABCC4 | |
| SCHEMBL14780849 | 0.88 | CDC25A (0.71) | VDRUSP2GPBAR1CDC25AABCC4 | |
| SCHEMBL10602107 | 0.88 | CDC25A (0.71) | VDRUSP2GPBAR1CDC25AABCC4 | |
| SCHEMBL4735308 | 0.87 | VDR (0.58) | VDRUSP2GPBAR1CDC25AABCC4 | |
| SCHEMBL4739495 | 0.86 | VDR (0.57) | VDRUSP2GPBAR1CDC25AABCC4 | |
| SCHEMBL4739235 | 0.86 | CDC25A (0.61) | VDRUSP2GPBAR1CDC25AABCC4 | |
| SCHEMBL21928679 | 0.86 | VDR (0.60) | VDRUSP2GPBAR1CDC25AABCC4 | |
| SCHEMBL18575951 | 0.86 | VDR (0.77) | VDRUSP2GPBAR1ABCC4ST6GAL1 | |
| SCHEMBL11054624 | 0.86 | VDR (0.66) | VDRUSP2GPBAR1ABCC4ST6GAL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210347810-A1 | STEROL PURIFICATION | ARES CAPITAL CORPORATION, AS AGENT | 2021-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210347810-A1 | STEROL PURIFICATION | CYP46A1, CETP, SREBF2 | VDR 165/4885USP2 1731/4885GPBAR1 207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.